Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: GlaxoSmithKline | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: GlaxoSmithKline

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

GlaxoSmithKline

4Q Revenues: $12.1 billion (+5%)

4Q Earnings: $2.2 billion (-6%)

FY Revenues: $45.4 billion (+6%)

FY Earnings: $10.6 billion (+4%)
 
Comments: Advair sales were $7.0 billion for the year (+15%) and $1.9 billion in the quarter (+12%). Lamictal sales were $2.2 billion for the year (+22%) and $610 million in the quarter (+22%). Avandia sales dropped 31% to $1.8 billion for the year, and $327 million in the quarter (-48%), due to reports that linked the drug to an increased risk of heart attacks. Restructuring costs were $522 million in the quarter. R&D expenses for the year were $6.7 billion (+5%), and $2.1 billion in the quarter (+11%).

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters